International Journal of Research in Medical Sciences
Taiwade PD. Int J Res Med Sci. 2026 Dec;14(12):6037-6048
www.msjonline.org
pISSN 2320-6071 | eISSN 2320-6012
DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20264524

Review Article

The evolving role of clinical microbiologists in the era of antimicrobial resistance: from diagnostic experts to strategic leaders in healthcare

Pooja Dilip Taiwade*

Department of Microbiology, Government Medical College and Hospital, Nagpur, Maharashtra, India

Received: 08 October 2026
Revised: 17 November 2026
Accepted: 18 November 2026

***Correspondence:**
Dr. Pooja Dilip Taiwade,
E-mail: pooja.2209@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Antimicrobial resistance (AMR) is a major global health challenge that threatens the effectiveness of antimicrobial therapy and complicates the management of infectious diseases. The increasing prevalence of multidrug-resistant pathogens contributes to treatment failure, increased morbidity and mortality, prolonged hospitalization, and rising healthcare expenditure. In this context, clinical microbiology has evolved from a predominantly laboratory-based discipline into an essential component of integrated patient care, infection prevention, and public health. Clinical microbiologists now contribute to diagnostic stewardship, antimicrobial stewardship (AMS), healthcare-associated infection surveillance, outbreak investigation, molecular epidemiology, and evidence-based healthcare policy. Advances in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), molecular diagnostics, whole-genome sequencing, metagenomics, and artificial intelligence (AI) have further expanded the scope of microbiology practice. Nevertheless, challenges related to infrastructure, workforce capacity, diagnostic accessibility, interdisciplinary communication, and equitable implementation of emerging technologies persist, particularly in resource-limited settings. This narrative review examines the changing role of clinical microbiologists in the era of AMR, emphasizing their contributions to clinical decision-making, laboratory quality, infection prevention, surveillance, and healthcare leadership. It also discusses the challenges and future opportunities associated with precision diagnostics, genomic surveillance, digital technologies, and the One Health approach. Strengthening the clinical integration of microbiology services and recognizing microbiologists as strategic partners in healthcare are essential for improving patient outcomes and supporting sustainable AMR containment.

Keywords: Antimicrobial resistance, Clinical microbiology, Antimicrobial stewardship, Diagnostic stewardship, Infection prevention and control, Molecular diagnostics, Genomic epidemiology, One health

INTRODUCTION

The discovery of penicillin by Alexander Fleming marked a major turning point in the history of modern medicine and laid the foundation for effective antimicrobial therapy. However, the subsequent emergence of AMR demonstrated the limitations of antimicrobial agents when they are used inappropriately. Fleming's early observations on the consequences of inadequate antimicrobial exposure continue to hold relevance in the present era, particularly in the context of strategies aimed at preventing and controlling AMR.[1]

AMR refers to the ability of microorganisms to survive or multiply despite exposure to antimicrobial agents that would normally inhibit their growth or eliminate them. It has become a major global public health concern and requires coordinated efforts from healthcare institutions, research organisations, and public health systems.[2] A systematic analysis estimated that bacterial AMR was directly responsible for approximately 1.27 million deaths and was associated with nearly 4.95 million deaths worldwide in 2019.[3] Subsequent global surveillance studies have further highlighted the considerable burden of infections caused by antimicrobial-resistant organisms.[4]

The impact of AMR is not limited to the treatment of routine infectious diseases. Resistant infections can affect the safety and outcome of major surgical procedures, cancer chemotherapy, organ transplantation, neonatal care, and intensive care management. These medical interventions often depend on the availability of effective antimicrobial agents for prophylaxis and treatment. Therefore, the increasing prevalence of AMR poses a serious challenge to the delivery of safe and effective healthcare services.[5]

The emergence and spread of AMR are associated with several factors, including inappropriate antimicrobial prescribing, unnecessary or prolonged antibiotic use, inadequate infection prevention and control practices, limited diagnostic facilities, and insufficient surveillance. The transmission of resistant microorganisms between humans, animals, healthcare settings, and the environment further contribute to the complexity of this problem.[6,7] Addressing these factors requires appropriate antimicrobial use, improved diagnostic practices, effective surveillance systems, and consistent implementation of infection prevention measures.

Traditionally, clinical microbiologists were mainly involved in the isolation, identification, and antimicrobial susceptibility testing (AST) of clinically significant microorganisms. These activities continue to form the basis of clinical microbiology practice. However, with the increasing burden of antimicrobial-resistant infections, the responsibilities of clinical microbiologists have gradually expanded. They are now involved in clinical consultation, interpretation of complex resistance patterns, AMS activities, outbreak investigations, infection prevention strategies, and the development of the institutional policies.[8,9]

In this regard, the present review discusses the changing role and responsibilities of clinical microbiologists in the era of AMR. Particular emphasis has been given to diagnostic stewardship, AMS, infection prevention and control, emerging diagnostic technologies, genomic epidemiology, the One Health approach, and the growing involvement of clinical microbiologists in healthcare leadership.

GLOBAL BURDEN AND DETERMINANTS OF AMR

Global burden and clinical implications

The global burden of bacterial AMR includes deaths directly attributable to resistant infections as well as deaths associated with infections in which AMR contributes to delayed or ineffective treatment. Patients with resistant infections often require prolonged hospitalisation, more complex treatment regimens, additional diagnostic investigations, and the use of expensive or potentially toxic antimicrobial agents. These factors increase the overall cost of healthcare and place an additional burden on existing healthcare infrastructure.[3,5]

The frequently quoted estimate of approximately 10 million deaths annually due to AMR by 2050 originated from the Review on AMR published in 2016. This figure represents a projected scenario rather than a definite prediction of future mortality. The actual burden of AMR in the coming years will depend on several factors, including patterns of antimicrobial consumption, implementation of infection prevention measures, availability of appropriate healthcare facilities, surveillance capacity, and the effectiveness of control strategies.[5]

The burden and clinical consequences of AMR are not uniform across geographical regions or population groups. Differences in healthcare infrastructure, availability of diagnostic facilities, access to effective antimicrobial treatment, patterns of antimicrobial consumption, and prevalence of underlying diseases influence the occurrence and outcome of resistant infections. Healthcare settings with limited microbiological laboratory facilities may face additional difficulties in detecting resistant pathogens, identifying changing resistance patterns, and initiating appropriate targeted treatment.[2-4]

Drivers of AMR

The development and spread of AMR involve a complex interaction of biological mechanisms, clinical practices, human behaviour, and environmental factors. Inappropriate antimicrobial prescribing, unnecessary treatment of viral infections, incorrect dosing, inappropriate duration of therapy, poor patient adherence, and antimicrobial use without proper clinical assessment contribute to the selection and spread of resistant microorganisms.[6,7]

Within healthcare facilities, delayed identification of pathogens, inadequate microbiological investigations, overcrowding, inappropriate antimicrobial exposure, and deficiencies in infection prevention and control practices can facilitate the emergence and transmission of resistant organisms. In the community, self-medication and the availability of antimicrobial agents without appropriate prescription or medical supervision further contribute to their inappropriate use.

The use of antimicrobial agents in food-producing animals also contributes to the development and spread of AMR. Resistant microorganisms and resistance determinants can be transmitted through the food chain, contaminated water, wastewater, agricultural practices, and other environmental routes. These interconnected pathways indicate that AMR cannot be controlled through interventions limited to human healthcare alone. A coordinated approach involving human, animal, and environmental health sectors is therefore necessary.[2,7]

The need for coordinated action

The control of AMR requires a coordinated approach involving healthcare professionals, microbiology laboratories, public health authorities, and other relevant sectors. Important measures include effective AMS programmes, accessible and reliable diagnostic services, appropriate infection prevention and control practices, public awareness, regulatory measures, and strengthened surveillance systems.

Clinical microbiologists contribute to these efforts by translating laboratory findings into clinically useful information and supporting evidence-based treatment decisions. Their knowledge of pathogen identification, AST, resistance mechanisms, and laboratory surveillance makes them important contributors to institutional AMR control programmes as well as broader public health initiatives.

EVOLUTION OF CLINICAL MICROBIOLOGY: FROM LABORATORY SERVICE TO CLINICAL PARTNERSHIP

Traditionally, clinical microbiology has focused on the processing of clinical specimens, Traditionally, clinical microbiology has been concerned with the processing of clinical specimens, identification of pathogenic microorganisms, AST, and timely reporting of laboratory findings. These activities remain essential for the diagnosis and management of infectious diseases. However, with the increasing complexity of antimicrobial-resistant infections and the growing emphasis on appropriate antimicrobial use, the scope of clinical microbiology has gradually expanded.

The role of the modern clinical microbiologist is not limited to identifying microorganisms and reporting their susceptibility patterns. Laboratory findings need to be interpreted in relation to the patient's clinical condition, quality of the specimen, previous antimicrobial exposure, underlying medical conditions, and relevant epidemiological information. The isolation of a microorganism from a clinical specimen does not always indicate an active infection. Depending on the organism and the type of specimen, the finding may represent colonisation or contamination rather than a clinically significant infection. Proper interpretation is therefore important to avoid the un-necessary antimicrobial treatment and to ensure that appropriate therapy is not delayed.[8]

The introduction of rapid microbial identification techniques and molecular diagnostic methods has further increased the need for interaction between microbiology laboratories and clinical teams. Although these technologies have reduced the time required for identification of several pathogens, their usefulness depends on correct interpretation of the results and timely communication with treating clinicians.[9,10]

Clinical microbiology is therefore gradually moving beyond its traditional role as a laboratory reporting service towards a more clinically integrated discipline. The responsibilities of clinical microbiologists now include assessment of the clinical significance of laboratory findings, suggesting additional investigations when required, providing guidance on antimicrobial selection, participating in infection prevention activities, and identifying unusual resistance patterns that may indicate emerging threats or possible transmission within healthcare settings.

This expansion of responsibilities does not reduce the importance of accurate laboratory procedures and quality assurance. Rather, it emphasises the need to combine technical laboratory expertise with appropriate clinical interpretation and effective communication to ensure the delivery of reliable microbiological services.

DIAGNOSTIC STEWARDSHIP: OPTIMIZING THE USE OF MICROBIOLOGY INVESTIGATIONS

Diagnostic stewardship refers to the appropriate selection, utilisation, performance, interpretation, and reporting of diagnostic investigations to improve patient management and avoid unnecessary healthcare interventions. Its importance has increased in the era of AMR, as inappropriate test ordering, improper specimen collection, and incorrect interpretation of laboratory findings may lead to unnecessary antimicrobial exposure, delayed diagnosis, or failure to identify clinically significant pathogens.[8,11]

Appropriate test selection and specimen quality

Clinical microbiologists can guide clinicians in selecting appropriate microbiological investigations according to the suspected site of infection, clinical presentation, and relevant patient-related risk factors. Appropriate selection of investigations helps avoid unnecessary testing and increases the possibility of obtaining results that are clinically useful.

Specimen quality is equally important for obtaining reliable microbiological results. Improper specimen collection, inadequate transport conditions, delays in processing, and contamination can affect the accuracy of laboratory investigations and their subsequent interpretation. Clinical microbiologists should therefore be involved in developing specimen collection guidelines, establishing specimen rejection criteria, educating healthcare personnel, and monitoring pre-analytical errors. These measures help improve the overall quality and reliability of microbiological investigations.[8]

Interpretation of results in clinical context

Microbiological findings should always be interpreted in relation to the patient's clinical condition and relevant epidemiological information. Differentiating true infection

from colonisation or contamination is particularly important when interpreting specimens collected from non-sterile body sites or during screening investigations.

Considering colonisation as an active infection may result in unnecessary antimicrobial treatment, increased selection pressure, and avoidable adverse effects. On the other hand, failure to recognise a clinically significant isolate may delay appropriate treatment and adversely affect patient outcomes. Clinical microbiologists can help avoid these situations by providing interpretive comments, discussing doubtful or clinically significant findings with treating clinicians, and suggesting repeat sampling or additional investigations whenever required.[8,11]

Diagnostic stewardship and antimicrobial use

Diagnostic stewardship and AMS are closely related and together form an important part of AMR control. Appropriate microbiological investigations help in early identification of pathogens and selection of targeted antimicrobial therapy. However, unnecessary testing and improper interpretation of results may contribute to inappropriate antimicrobial prescribing and continuation of treatment without adequate justification.[11]

A diagnostic stewardship programme may include standardised criteria for test ordering, improvement in specimen collection practices, regular audits of laboratory utilisation, interpretive reporting, and feedback to clinicians. The effectiveness of such programmes should be assessed through clinically relevant outcomes and appropriate performance indicators rather than simply measuring a reduction in no. of laboratory investigations.

The usefulness of diagnostic stewardship ultimately depends on whether the investigations performed provide reliable information that can be appropriately utilised for timely and effective patient management.

AMS: TRANSLATING LABORATORY RESULTS INTO TREATMENT DECISIONS

AMS refers to a coordinated approach aimed at ensuring the appropriate selection, dose, route, and duration of antimicrobial treatment while reducing unnecessary antimicrobial exposure, adverse effects, and the development of resistance. Clinical microbiologists are important members of AMS programmes because microbiological investigations provide the necessary information for selecting targeted antimicrobial therapy and improving prescribing practices.[12-15]

AST and interpretation

AST is one of the most important components of clinical microbiology, as it provides information regarding the *in vitro* activity of antimicrobial agents against clinically significant bacterial isolates. Reliable interpretation of AST results requires standardised laboratory procedures, appropriate quality control, validated interpretive criteria, and an understanding of limitations of individual testing methods.[8]

Minimum inhibitory concentration (MIC) values, wherever available and relevant, provide additional information regarding concentration of an antimicrobial agent required to inhibit visible microbial growth under standardised laboratory conditions. These values can help in understanding susceptibility patterns and may be useful during clinical discussions regarding antimicrobial treatment. However, MIC results should always be interpreted according to applicable susceptibility testing standards, organism-specific recommendations, site of infection, and other relevant clinical factors.

It is also important to understand that *in vitro* susceptibility does not always guarantee a favourable clinical outcome. Antimicrobial pharmacokinetics and pharmacodynamics, drug penetration at the site of infection, immune status of the patient, severity of infection, and adequate source control can all influence treatment response. Therefore, clinical microbiologists should communicate susceptibility results in a way that supports clinical decision-making rather than treating laboratory findings as the sole basis for selecting therapy.

Institutional antibiograms and resistance surveillance

Cumulative antibiograms provide information regarding local antimicrobial susceptibility patterns and are useful in selecting empirical antimicrobial treatment. Clinical microbiologists are responsible for ensuring appropriate collection, validation, analysis, and presentation of susceptibility data used for preparing these reports.

Several methodological aspects need to be considered while preparing reliable antibiograms. These include appropriate selection of isolates, exclusion of duplicate isolates from same patient wherever applicable, availability of an adequate number of isolates, and clearly defined reporting periods. Standardised methods of data analysis and presentation are also necessary to ensure meaningful interpretation and comparison of resistance patterns.[8,12]

Antibiograms should be updated periodically and interpreted along with patient-specific clinical information, previous microbiological findings, severity of infection, and institutional treatment guidelines. Apart from guiding empirical therapy, regular analysis of antibiogram data can help identify changing resistance patterns and indicate the need for further investigation or modification of institutional antimicrobial prescribing guidelines.

De-escalation and targeted therapy

Microbiological results provide an opportunity to review empirical antimicrobial treatment and modify therapy

according to the identified pathogen and its susceptibility pattern. Depending on the clinical condition, this may involve narrowing the antimicrobial spectrum, discontinuing unnecessary agents, changing the route of administration, or selecting a more appropriate alternative.

Clinical microbiologists contribute to these decisions by ensuring timely communication of important laboratory findings, explaining relevant resistance mechanisms, and discussing the clinical significance of susceptibility results with treating clinicians.[12-15]

For example, identification of a multidrug-resistant Gram-negative organism may require additional susceptibility testing, consideration of alternative antimicrobial agents, and assessment of the need for appropriate infection prevention measures. Similarly, microbiological findings that do not support a bacterial cause of infection may provide an opportunity to reconsider the continuation of unnecessary antibacterial treatment. However, such decisions should always be made after considering the clinical presentation, limitations of the diagnostic methods used, and the possibility of infection despite negative microbiological findings.

Multidisciplinary stewardship programs

Effective AMS requires the active involvement of clinical microbiologists, infectious disease specialists, pharmacists, treating clinicians, infection prevention personnel, and hospital administrators. Participation from different specialties ensures that antimicrobial treatment decisions are based on microbiological findings, clinical assessment, pharmacological considerations, and local resistance patterns.

Common AMS interventions include prospective audit and feedback, preauthorisation of selected antimicrobial agents, regular review of microbiological reports, preparation of institutional treatment guidelines, and educational activities for healthcare professionals.[12-15]

The contribution of clinical microbiologists to these programmes extends beyond providing laboratory reports. Their involvement in clinical discussions, interpretation of resistance patterns, and identification of opportunities for modification of antimicrobial treatment helps connect laboratory findings with appropriate clinical practice.

Active participation in multidisciplinary stewardship programmes can therefore improve antimicrobial prescribing practices, reduce unnecessary exposure and strengthen institutional efforts to control AMR.

INFECTION PREVENTION AND CONTROL

Infection prevention and control (IPC) is an important component of strategies aimed at reducing the emergence and transmission of antimicrobial-resistant microorganisms in healthcare settings. Clinical microbiologists contribute to IPC activities through microbiological surveillance, identification of suspected outbreaks, laboratory investigations, and interpretation of findings that help guide infection control measures.

Healthcare-associated infection surveillance

Clinical microbiology laboratories provide important data for the identification, monitoring, and investigation of healthcare-associated infections (HAIs). When microbiological findings are correlated with clinical information and standardised surveillance definitions, they can help identify changes in infection rates, distribution of pathogens, and AMR patterns within healthcare facilities.[16,18]

Clinical microbiologists work in coordination with infection prevention and control teams to interpret surveillance data, identify unusual clusters of infections, and recognise microorganisms that may require further epidemiological investigation. Such surveillance helps in the early identification of possible transmission events and in assessing the effectiveness of existing infection control measures.

However, microbiological surveillance data should be interpreted carefully. Differences in specimen collection practices, diagnostic protocols, laboratory methods, and patient populations can influence the reported frequency of infections. Therefore, appropriate clinical correlation and standardised surveillance methods are necessary for obtaining reliable information.

Outbreak investigation and transmission assessment

The microbiology laboratory has an important role in the investigation of suspected healthcare-associated outbreaks. Laboratory investigations help identify the microorganisms involved, determine their antimicrobial susceptibility patterns, and compare isolates to assess whether they may be epidemiologically related. Conventional microbial typing methods and advanced molecular techniques provide additional information regarding possible transmission relationships.[21-23]

The findings of these investigations help infection prevention teams in making decisions regarding patient screening, isolation precautions, environmental assessment, and implementation of appropriate control measures. Successful outbreak investigation requires timely communication and coordination between microbiology laboratories, infection prevention personnel, clinical departments, and hospital administration.[16,21]

Clinical microbiologists also interpret laboratory findings in relation to patient movement, clinical exposure history, and available epidemiological information. Such correlation is important to differentiate possible transmission events from unrelated infections caused by organisms with similar microbiological characteristics.

Environmental surveillance and infection control

Environmental microbiological surveillance may be useful during selected outbreak investigations or when a particular environmental source is suspected to be involved in pathogen transmission. However, environmental sampling should be undertaken only when there is a clear clinical or epidemiological indication rather than as a routine activity without a specific objective.

Clinical microbiologists can guide the selection of appropriate sampling sites, laboratory methods, and interpretation of environmental culture results. Their expertise is particularly useful in differentiating findings that may be epidemiologically significant from incidental environmental contamination, which could otherwise lead to unnecessary infection control interventions.

The interpretation of environmental surveillance findings should take into consideration the suspected route of transmission, characteristics of the organism, and clinical circumstances. Coordination with infection prevention teams is necessary to ensure that environmental investigations provide useful information for infection control decisions.

Supporting evidence-based IPC practices

Prevention of healthcare-associated transmission depends on the consistent implementation of established infection control measures, including hand hygiene, appropriate isolation precautions, environmental cleaning and disinfection, and adherence to safe healthcare practices. These measures remain essential for limiting the spread of resistant microorganisms within healthcare facilities.

Clinical microbiologists support IPC programmes by providing reliable laboratory information, identifying clinically significant pathogens, interpreting surveillance findings, and contributing to the evaluation of infection control interventions.[16-18]

Their involvement also helps in developing institutional infection prevention policies according to local pathogen distribution and AMR patterns. In this way, clinical microbiology provides an important connection between laboratory surveillance and practical infection prevention measures.

MOLECULAR DIAGNOSTICS AND GENOMIC EPIDEMIOLOGY

Advances in diagnostic technologies have considerably improved the ability of clinical microbiology laboratories to identify microorganisms rapidly and accurately. Molecular diagnostic methods and advanced identification techniques complement conventional culture-based methods and provide additional information that is useful in the diagnosis, management, and epidemiological investigation of infectious diseases.[9,19]

MALDI-TOF mass spectrometry

MALDI-TOF MS is an advanced technique used for microbial identification based on characteristic protein profiles. Compared with conventional biochemical identification methods, MALDI-TOF MS can considerably reduce the time required for identification once an adequate microbial isolate is available.[20]

The performance of this technique depends on several factors, including the type of microorganism, database coverage, specimen processing methods, and laboratory validation. Although MALDI-TOF MS has considerable advantages in routine microbial identification, it cannot completely replace conventional culture methods or comprehensive AST.

Moreover, identification of a microorganism by MALDI-TOF MS does not necessarily provide information regarding its complete AMR profile. Detection of specific resistance mechanisms may require additional phenotypic or molecular investigations. Therefore, MALDI-TOF MS should be considered an important part of the overall microbiological diagnostic process rather than a replacement for established laboratory methods.

Molecular assays and multiplex diagnostics

Molecular diagnostic techniques, including polymerase chain reaction (PCR), multiplex molecular panels, and other nucleic acid amplification methods, have improved the rapid detection of selected infectious agents and AMR determinants. These methods are particularly useful in situations where early identification of a pathogen or resistance marker may influence treatment decisions or infection prevention measures.[19]

Multiplex molecular assays allow simultaneous detection of multiple microorganisms and selected resistance-associated genetic targets in a single investigation. This can help in obtaining an early diagnosis in certain clinical conditions and reduce the time required to identify specific microbiological targets.

Despite these advantages, molecular diagnostic methods have certain limitations. Detection of microbial genetic material does not necessarily confirm the presence of viable microorganisms or establish that the detected organism is responsible for the patient's illness. Similarly, identification of a resistance-associated gene does not always provide a complete picture of the organism's phenotypic susceptibility. Targeted molecular assays may also fail to detect microorganisms or resistance mechanisms that are not included in the assay design.

Clinical microbiologists therefore have an important responsibility in interpreting molecular results along with specimen characteristics, clinical presentation, epidemiological information, and other microbiological findings. Proper integration of molecular methods with

conventional diagnostic techniques is necessary for meaningful interpretation of results.

Whole-genome sequencing

Whole-genome sequencing (WGS) has become an important tool in clinical microbiology and genomic epidemiology. It provides detailed information regarding microbial genetic relatedness, AMR determinants, and patterns of pathogen evolution. Its application has improved the investigation of selected healthcare-associated outbreaks by allowing high-resolution comparison of isolates and helping identify possible transmission relationships.[21-23]

Apart from outbreak investigations, WGS can be used for surveillance of emerging resistant clones, characterisation of resistance mechanisms, and investigation of genetic diversity among clinically important pathogens. These applications provide useful information regarding the epidemiology and spread of antimicrobial-resistant organisms.

However, genetic similarity between isolates should not be considered definitive evidence of direct transmission between patients. Genomic findings need to be correlated with epidemiological information, including patient admission dates, ward locations, movement histories, and possible exposure events. Such correlation is important for understanding the possible direction and circumstances of transmission.

Routine implementation of WGS also involves several practical difficulties, including financial constraints, infrastructure requirements, availability of trained personnel, bioinformatics expertise, turnaround time, and the need for standardised analytical and interpretive methods. Therefore, its use should be guided by the specific clinical or epidemiological requirement and the resources available within the institution.

Metagenomics and emerging diagnostic approaches

Metagenomic sequencing is an emerging diagnostic approach that allows detection of microbial genetic material directly from clinical specimens. Unlike targeted molecular assays, metagenomic techniques can investigate a wider range of microorganisms without requiring prior selection of a specific pathogen.

This approach may be particularly useful in selected cases where the cause of infection remains unidentified despite routine culture-based and targeted molecular investigations.

However, interpretation of metagenomic results is associated with several difficulties. These include the presence of large amounts of host-derived genetic material, contamination during specimen collection or processing, detection of microorganisms with uncertain clinical significance, and difficulty in differentiating colonisation from active infection. The high cost, technical requirements, and limited availability of these investigations also restrict their routine use in clinical practice.

The introduction of metagenomic sequencing and other emerging diagnostic methods should therefore depend on their demonstrated clinical usefulness, diagnostic performance, laboratory capacity, and affordability. These technologies are likely to provide the greatest benefit when their findings can be appropriately interpreted and used to guide clinical decisions.

THE ONE HEALTH APPROACH TO AMR

The One Health approach recognises the close relationship between human, animal, and environmental health and emphasises the need for coordinated efforts across these sectors. Antimicrobial-resistant microorganisms and resistance determinants can circulate between humans, animals, and the environment through different routes, including direct contact, food production and consumption, water systems, wastewater, and environmental contamination.[2,24]

Clinical microbiologists can contribute to One Health activities through the identification and characterisation of resistant pathogens, investigation of AMR mechanisms, and participation in integrated surveillance programmes. Collaboration between clinical, veterinary, environmental, and public health laboratories can improve understanding of the distribution and transmission of resistant microorganisms and resistance determinants across different sectors.

In India and other countries facing a considerable burden of AMR, strengthening laboratory infrastructure and surveillance networks is particularly important. National and regional surveillance programmes provide useful information regarding priority bacterial pathogens, geographical variations in antimicrobial susceptibility, and emerging resistance patterns. Such information can help in formulating evidence-based antimicrobial policies and infection prevention strategies.[25]

An effective One Health framework requires standardised surveillance methods, reliable laboratory facilities, appropriate data-sharing systems, and continuous coordination between the concerned sectors. Clinical microbiologists can contribute through their expertise in microbial identification, AST, laboratory quality assurance, and interpretation of surveillance findings.

However, controlling AMR through the One Health approach requires efforts beyond the healthcare laboratory. Coordinated policies involving human healthcare, veterinary medicine, agriculture, food safety, and environmental management are necessary to address the different factors contributing to AMR.[2,24]

AI AND DIGITAL TRANSFORMATION IN CLINICAL MICROBIOLOGY

AI, machine learning, and laboratory automation are emerging technologies that may bring significant changes to the practice of clinical microbiology. Their applications include automated image analysis, interpretation of microbiological data, prioritisation of critical laboratory results, prediction of AMR patterns, and identification of unusual trends in epidemiological surveillance data.[26]

AI-based tools may help in combining microbiological findings with relevant clinical and epidemiological information, thereby supporting more efficient clinical decision-making. For example, predictive algorithms may help identify patients requiring urgent clinical attention following the detection of positive blood cultures or identify unusual antimicrobial susceptibility patterns that require further investigation. However, these applications need appropriate validation before their introduction into routine clinical practice.

The accuracy and reliability of AI-based systems largely depend on the quality, completeness, and representativeness of the data used for their development and validation. Algorithms developed using data from a particular healthcare institution may not perform equally well in other settings because of differences in patient characteristics, distribution of pathogens, laboratory methods, antimicrobial prescribing practices, and local resistance patterns.[26]

The use of AI in clinical microbiology also raises concerns regarding transparency of algorithms, professional accountability, patient confidentiality, data management, and the consequences of incorrect automated recommendations. Clinical microbiologists should therefore understand these technologies, assess their reliability, and remain aware of their limitations rather than depending entirely on automated results.

AI should be considered a supportive tool for clinical decision-making and not a replacement for professional judgement and clinical expertise. Its successful introduction into microbiology practice will depend on whether it can improve diagnostic accuracy, turnaround time, laboratory efficiency, and patient outcomes while maintaining appropriate standards of safety and reliability.

CHALLENGES FACING CONTEMPORARY CLINICAL MICROBIOLOGY

Despite advances in diagnostic technologies and the expanding responsibilities of clinical microbiologists, several challenges continue to affect the effective integration of microbiology services into AMR control strategies. These challenges are related to laboratory infrastructure, availability of trained personnel, communication between laboratories and clinical teams, increasing workload, and unequal access to advanced diagnostic facilities.

Infrastructure and resource limitations

The introduction and maintenance of advanced diagnostic technologies require adequate financial resources, trained laboratory personnel, reliable equipment, regular maintenance, quality assurance systems, and appropriate laboratory information infrastructure. Meeting these requirements may be particularly difficult for healthcare institutions and laboratories functioning with limited resources.[2,4,25]

Inadequate infrastructure can affect timely pathogen identification, availability of AST, implementation of molecular diagnostic methods, and regular surveillance of AMR. These limitations may delay appropriate treatment decisions and reduce the ability of laboratories to identify emerging resistance patterns.

Therefore, strengthening basic microbiology laboratory services should remain a priority along with the introduction of advanced diagnostic technologies. Investment in essential laboratory infrastructure, reliable culture facilities, standardised susceptibility testing, and quality management systems is necessary to maintain sustainable microbiology services.

Workforce development and training

The present-day practice of clinical microbiology requires a combination of technical laboratory skills, clinical interpretation, epidemiological knowledge, communication skills, and familiarity with newer diagnostic technologies. As a result, the responsibilities of clinical microbiologists are gradually extending beyond conventional laboratory procedures.

Training programmes should include competencies related to AST, interpretation of complex resistance mechanisms, molecular diagnostics, genomic epidemiology, AMS, infection prevention, and laboratory quality management.

Continuing professional development is equally important to maintain competency in rapidly changing diagnostic technologies and updated laboratory standards. Regular training programmes and opportunities for interaction with different clinical specialties can help prepare microbiologists for their expanding professional responsibilities.

Communication between laboratories and clinical teams

The usefulness of microbiological investigations depends not only on the accuracy of laboratory results but also on their timely reporting and proper interpretation. Delayed reporting, inadequate clinical correlation, and poor communication between microbiology laboratories and treating teams may result in unnecessary antimicrobial

exposure, missed opportunities for treatment de-escalation, and delays in implementing infection prevention measures.[11-15]

Improvement in communication requires appropriate laboratory reporting systems, prompt notification of critical results, multidisciplinary case discussions, and active participation of microbiologists in clinical consultations and ward-based activities.

Direct interaction between microbiologists and treating clinicians helps in clarifying complex laboratory findings, improving understanding of antimicrobial susceptibility results, and making more appropriate treatment decisions.

Workload, quality assurance, and occupational stress

The increasing number of microbiological investigations, additional surveillance responsibilities, complex diagnostic procedures, and shortage of laboratory personnel place considerable demands on microbiology services. These factors may contribute to occupational stress and can affect laboratory efficiency, turnaround time, and consistency in diagnostic procedures.

Healthcare institutions should therefore give adequate attention to staffing, professional development, laboratory quality management, and proper organisation of laboratory workflows. Automation and digital technologies may help reduce certain operational difficulties; however, their introduction should be accompanied by appropriate validation, monitoring, and professional supervision.

Maintaining staff competency and occupational well-being is important for ensuring the long-term quality and sustainability of microbiology services.

Unequal access to innovation

Although advanced diagnostic technologies provide opportunities to improve infectious disease diagnosis and AMR surveillance, their availability remains uneven across healthcare institutions and geographical regions. Differences in financial resources, technical infrastructure, trained personnel, and access to specialised laboratory services contribute to variations in the diagnostic capacity.

The introduction of new technologies should therefore be based on local healthcare requirements, disease burden, affordability, cost-effectiveness, and the availability of supporting clinical services.

A balanced approach should focus on strengthening essential microbiology services while introducing advanced diagnostic methods wherever their expected clinical and public health benefits justify the investment. Equitable access to reliable diagnostic facilities is particularly important for reducing differences in the diagnosis and management of antimicrobial-resistant infections.

THE MD MICROBIOLOGIST'S PERSPECTIVE: CLINICAL INTERPRETATION AND PROFESSIONAL LEADERSHIP

From the perspective of postgraduate medical microbiology training, the clinical microbiologist has an important position at the interface of laboratory medicine, clinical practice, infection prevention, and public health. The role requires more than technical knowledge of laboratory investigations. It also involves interpreting microbiological findings in relation to the patient's clinical condition and understanding the limitations of individual diagnostic methods.[8,12-15]

Beyond laboratory reporting

An MD microbiologist should be able to assess the technical reliability and clinical significance of laboratory findings in relation to the available patient information. This includes recognising possible specimen contamination, interpreting complex antimicrobial susceptibility patterns, understanding relevant resistance mechanisms, and identifying situations where additional investigations or the specialist consultation may be required.

The ability to communicate laboratory findings clearly to treating clinicians is equally important. Even technically accurate results may not provide adequate clinical benefit if they are misunderstood, incorrectly interpreted, or not considered during patient management.

Therefore, the professional responsibilities of an MD microbiologist include laboratory accuracy, critical interpretation, clinical correlation, and effective communication.

Participation in multidisciplinary decision-making

Participation in multidisciplinary clinical discussions allows microbiologists to contribute directly to the diagnosis and management of infectious diseases. Their involvement may include interpretation of culture and antimicrobial susceptibility results, suggestions regarding additional diagnostic investigations, explanation of resistance patterns, and guidance regarding appropriate modifications in antimicrobial treatment.[12-15]

Such involvement is particularly useful in the management of bloodstream infections, infections caused by multidrug-resistant organisms, suspected healthcare-associated outbreaks, and clinically complicated cases where routine microbiological findings may not adequately explain the patient's condition.

Through regular interaction with treating clinicians, clinical microbiologists can help ensure that laboratory findings are appropriately considered during treatment decisions and implementation of infection prevention measures.

Academic and institutional responsibilities

Apart from diagnostic and clinical responsibilities, postgraduate medical microbiologists are also involved in academic teaching, research activities, laboratory quality improvement, infection prevention education, and preparation of institutional guidelines.

Participation in these activities helps promote evidence-based practices and contributes to the improvement of microbiology services. Academic and research work also provides opportunities to study local AMR patterns, evaluate diagnostic methods, and identify areas where further improvement is required.

Professional leadership in clinical microbiology does not mean taking over the responsibilities of treating clinicians or other healthcare professionals. Rather, it involves providing specialised microbiological knowledge, encouraging multidisciplinary coordination, and supporting informed institutional decisions related to diagnosis, antimicrobial use, and infection prevention.

The future of clinical microbiology will depend on the effective integration of diagnostic services, clinical consultation, AMS, surveillance activities, and institutional decision-making. With the increasing burden of AMR, clinical microbiologists will be expected to contribute not only to individual patient management but also to broader public health strategies.

Several areas require particular attention for the further development of clinical microbiology.

FURTHER DEVELOPMENT OF CLINICAL MICROBIOLOGY

Strengthening laboratory clinical integration

Clinical microbiology services need to be more closely linked with clinical departments, AMS programmes, and infection prevention and control teams. Regular interaction between microbiologists and treating clinicians, along with timely communication of clinically significant findings, can improve the use of diagnostic results in patient management.[11-15]

Greater involvement of microbiologists in clinical consultations and multidisciplinary discussions can also help in the interpretation of complex microbiological findings and appropriate modification of antimicrobial treatment.

Expanding surveillance and data integration

Reliable surveillance systems are required to monitor AMR patterns, identify emerging pathogens, and recognise changes in the epidemiology of resistant infections. Improvement in laboratory data quality, standardised reporting practices, and development of regional and national laboratory networks can strengthen the ability to identify and respond to AMR.[2,4,25]

Integration of microbiological surveillance data with relevant clinical and epidemiological information may further improve the understanding of resistance patterns and the support evidence-based public health interventions.

Advancing precision diagnostics

Developments in rapid microbial identification, molecular detection of resistance markers, genomic analysis, and selected advanced diagnostic techniques provide opportunities to improve the accuracy and speed of infectious disease diagnosis. These methods may support more individualised antimicrobial treatment by providing information regarding pathogen identification and relevant resistance characteristics.[19-23]

However, the introduction of precision diagnostic technologies should depend on their diagnostic performance, clinical usefulness, affordability, and suitability for the healthcare setting in which they are being used. Their actual value depends on whether the information obtained can improve treatment decisions and patient outcomes.

Developing leadership and policy expertise

Clinical microbiologists should be encouraged to participate in the development and implementation of institutional antimicrobial policies, laboratory networks, infection prevention strategies, public health surveillance programmes, and national AMR initiatives.

Their knowledge of pathogen identification, resistance mechanisms, laboratory surveillance, and diagnostic quality can contribute to the development of evidence-based healthcare policies. Greater involvement in institutional and public health decision-making may help align laboratory services with broader healthcare requirements and strengthen coordinated efforts to control AMR.[2,24,25]

Promoting equitable and sustainable innovation

Advances in clinical microbiology should be supported by continuous investment in laboratory infrastructure, workforce development, quality assurance, equipment maintenance, and equal access to essential diagnostic services.

The introduction of new diagnostic technologies should be based on their demonstrated clinical and public health benefits rather than technological advancement alone. Sustainable improvement requires methods that are affordable, practical, and suitable for the healthcare settings in which they are expected to be used.

Strengthening basic microbiology services while introducing advanced technologies according to institutional requirements is an important approach to achieving equitable and sustainable improvements in the diagnosis and control of AMR.

CONCLUSION

The increasing burden of AMR has considerably expanded the responsibilities of clinical microbiologists and highlighted the importance of microbiology services in modern healthcare. Although microbial identification and AST remain the foundation of the specialty, the role of clinical microbiologists now extends to diagnostic stewardship, AMS, infection prevention and control, outbreak investigation, genomic surveillance, and institutional policy development.

Recent developments in molecular diagnostics, whole-genome sequencing, laboratory automation, and AI have provided new opportunities to improve the speed and accuracy of microbiological investigations. However, their effective use requires appropriate validation, skilled interpretation, adequate laboratory infrastructure, and proper integration into clinical practice.

Several challenges, including inadequate laboratory infrastructure, shortage of trained personnel, unequal access to advanced technologies, and gaps in communication between laboratories and clinical teams, continue to affect the effective utilisation of microbiological services. Addressing these issues requires sustained institutional support, continuous professional development, and better coordination between different healthcare disciplines.

Clinical microbiologists should therefore be recognised as important members of the healthcare team, with responsibilities extending from laboratory diagnosis to clinical interpretation, epidemiological surveillance, and professional leadership. Strengthening this integrated role is essential for effective AMR control and for ensuring safe, appropriate, and evidence-based patient care.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of *B. influenzae*. Bull World Health Organ. 2001;79(8):780-90.
2. World Health Organization. Global action plan on antimicrobial resistance. World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015. Available from: available at: https://iris.who.int/bitstream/handle/10665/193736/9789241509763_eng.pdf. Accessed on 16 July 2026.
3. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55.
4. World Health Organization. Global antibiotic resistance surveillance report 2025. Geneva: World Health Organization; 2025;114. Available at: https://www.who.int/publications/i/item/9789240116337. Accessed on 05 October 2026.
5. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Review on Antimicrobial Resistance. 2016.
6. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277-83.
7. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057-98.
8. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB Jr, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2013;57(4):e22-121.
9. van Belkum A, Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J, et al. Rapid clinical bacteriology and its future impact. Ann Lab Med. 2013;33(1):14-27.
10. Miller MB, Tang YW. Basic concepts of molecular microbiology and its applications in clinical microbiology. Clin Microbiol Rev. 2009;22(4):611-33.
11. Morgan DJ, Malani P, Diekema DJ. Diagnostic stewardship-leveraging the laboratory to improve antimicrobial use. JAMA. 2017;318(7):607-8.
12. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):847-56.
13. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77.
14. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-77.
15. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793-8.

16. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Am J Infect Control. 2007;35(10-2):S65-164.
17. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, et al. Evidence-based model for hand hygiene: a global initiative. Lancet Infect Dis. 2006;6(10):641-52.
18. Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic healthcare-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228-41.
19. Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem. 2015;61(1):100-11.
20. Didelot X, Bowden R, Wilson DJ, Peto TEA, Crook DW. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet. 2012;13(9):601-12.
21. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog. 2012;8(8):e1002824.
22. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al. Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. Sci Transl Med. 2012;4(148):148ra116.
23. Asnicar F, Thomas AM, Passerini A, Waldron L, Segata N. Machine learning for microbiologists. Nat Rev Microbiol. 2024;22(4):191-205.
24. Food and Agriculture Organization of the United Nations, United Nations Environment Programme, World Health Organization, World Organisation for Animal Health. One Health joint plan of action (2022-2026): working together for the health of humans, animals, plants and the environment. Geneva: World Health Organization; 2022;86. Available at: https://www.who.int/publications/i/item/9789240059139. Accessed on 05 October 2026.
25. Indian Council of Medical Research. Annual report: Antimicrobial Resistance Surveillance and Research Network (Jan 2024-Dec 2024). New Delhi: Indian Council of Medical Research; [year of publication not stated]. Available at: https://www.icmr.gov.in/post/annual-report-antimicrobial-resistance-surveillance-and-research-network-jan-2024-dec-2024. Accessed on 05 October 2026.
26. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. Geneva: World Health Organization; 2022;82. Available at: https://www.who.int/publications/i/item/9789240062702. Accessed on 05 October 2026.

Cite this article as: Taiwade PD. The evolving role of clinical microbiologists in the era of antimicrobial resistance: from diagnostic experts to strategic leaders in healthcare. Int J Res Med Sci 2026;14:6037-48.